{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"partial hematologic recovery (CRh)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"CR with incomplete blood count recovery (CRi)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"partial remission (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"morphologic leukemia free state (MLFS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"stable disease (SD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants with partial hematologic recovery (CRh), CR with incomplete blood count recovery (CRi), partial remission (PR), stable disease (SD), and morphologic leukemia free state (MLFS). CRh: neutrophils\\>5x10\\^8/L, platelets\\>5x10\\^10/L, BMB\\<5%, no peripheral blasts, no blasts with Auer rods, no extramedullary disease (EMD), not qualifying for CR. CRi: neutrophils \\<1x10\\^9/L or platelets\\<1x10\\^11/L; BMB \\<5%, no peripheral blasts, no blasts with Auer rods; no EMD; neutrophils or platelets not recovered; not qualifying for CRh. PR: neutrophils ≥1x10\\^9/L; platelets ≥1x10\\^11/L; blasts decreased to 5-25% and ≥50% decrease from pretreatment; blasts≤5% if Auer rod positive. SD: ≥3 months of absence of CR without minimal residual disease (CRMRD-), CR, CRh, CRi, PR, and MLFS, criteria for PD not met. MLFS: neutrophils \\<1x10\\^9/L and platelets\\<1x10\\^11/L, BMB\\<5%, no blasts with Auer rods; no EMD; neutrophils and platelets not recovered; not qualifying for CRi","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of 23 months","title":"Number of Participants With Disease-Specific Efficacy Measures in the AML Cohort","type":"SECONDARY","unitOfMeasure":"Participants"}